Amai Proteins' Sweet Victory: Clinical Data Paves Path to Market

REHOVOT, Israel – June 08, 2026 – In the fiercely competitive world of food ingredients, a press release is common, but a peer-reviewed publication in a top-tier scientific journal is a commercial power play. Today, Israeli food-tech firm Amai Proteins executed that play, announcing that the results of the world's first human clinical trial on the metabolic effects of a sweet protein have been published in Food Chemistry, one of the most respected journals in the field.

This isn't just an academic achievement; it's a critical commercialization milestone for the company's flagship product, sweelin®, a novel protein-based sweetener. The study confirms that sweelin® has no impact on blood glucose, insulin, or GLP-1 levels, providing the kind of hard, scientific validation that can unlock boardroom doors and accelerate deals with major food and beverage corporations. For Amai Proteins, this publication is the capstone on a meticulously built bridge from prototype to profit.

The Scientific Fortress

At the heart of today's announcement is a rigorous clinical study that sets a new standard for the sweetener industry. Conducted at the prestigious Tel Aviv Sourasky Medical Center under strict Good Clinical Practice (GCP) standards, the trial employed a double-blind, randomized, crossover design—the gold standard for clinical research. Healthy adult participants consumed beverages sweetened with either sweelin®, stevia, or glucose, and the results were unequivocal: sweelin® behaved as a complete metabolic neutral, causing no spike in blood sugar or the hormones that regulate it.

Publishing these findings in Food Chemistry is a strategic masterstroke. With a high impact factor of 9.8 and a reputation for rigorous peer review, the journal lends immense credibility to Amai's claims. It transforms marketing-speak into validated science, a crucial distinction for R&D departments at multinational food companies who are tasked with sourcing safe, effective, and trustworthy ingredients. This scientific validation provides a layer of assurance that goes far beyond a simple spec sheet, directly supporting customer adoption.

“Although not required by regulatory authorities, Amai Proteins decided to conduct this study to enhance consumer and market confidence in the safety and health profile of sweelin®,” said Dr. Amir Guttman, CEO of Amai Proteins. The move demonstrates a deep understanding of the market's underlying anxieties about sweeteners and a proactive strategy to build trust from the ground up.

Navigating a Crowded Market

The global demand for sugar reduction has created a multi-billion dollar market for alternative sweeteners, but it's a field littered with compromises. Consumers often complain about the bitter aftertaste of stevia, while some sugar alcohols like erythritol can cause digestive discomfort. Sweelin® aims to sidestep these issues entirely.

Derived from monellin, a protein found in the West African serendipity berry, sweelin® is approximately 3,000 times sweeter than sugar on a weight basis. Produced through precision fermentation—a process similar to brewing beer or making cheese—it can be scaled sustainably and cost-effectively. This advanced manufacturing process, combined with its protein-based nature, allows it to deliver a clean taste profile without the metabolic baggage of sugar or the formulation challenges of some rivals.

By proving its metabolic neutrality in a human trial, Amai Proteins has drawn a clear line in the sand. It’s not just competing on taste or sweetness intensity; it’s competing on health and transparency. In an era where consumers are increasingly tracking their metabolic health and using GLP-1-related medications, an ingredient that is “GLP-1-friendly” and doesn't disrupt the body's delicate hormonal balance is a significant differentiator. This positions sweelin® not merely as a sugar substitute, but as a high-performance health and wellness ingredient.

The Commercialization Expressway

This clinical publication is the latest and perhaps most powerful step in a deliberate commercialization strategy. It builds directly on a series of crucial regulatory victories that have de-risked the product for global partners. In February 2026, Amai secured Generally Recognized As Safe (GRAS) status from the U.S. Food and Drug Administration (FDA), opening the door to the massive American market. This was followed in May 2026 by approval from the Singapore Food Agency (SFA), establishing a key beachhead in the innovative Asia-Pacific region.

Together, these milestones form a trifecta of commercial readiness: regulatory approval, manufacturing scalability, and now, peer-reviewed clinical proof of its key health benefit. For a food and beverage manufacturer, this combination is incredibly compelling. It removes regulatory hurdles, ensures a stable supply chain, and provides a powerful, science-backed story to tell consumers. Amai reports that this milestone is already accelerating commercial discussions and product trials with U.S. customers, aiming to turn scientific validation into purchase orders.

By investing in a clinical trial that was not mandated by regulators, Amai Proteins has demonstrated that it is not just selling an ingredient, but a promise of safety, efficacy, and trust. This move provides its B2B customers with the confidence they need to reformulate iconic products and launch new lines of healthier foods and beverages, knowing the core sweetening ingredient is backed by unimpeachable science. In the journey from prototype to profit, Amai Proteins has shown that sometimes the fastest path to commercial success is paved with scientific rigor.